Literature DB >> 17048200

Renal tubular epithelial expression of the coinhibitory molecule B7-DC (programmed death-1 ligand).

Jingbo Zhang1, Yongwen Chen, Jingyi Li, Rui Zhang, Yi Wu, Liyun Zou, Tingting Zhao, Xiaoping Zhang, Junfeng Han, An Chen, Yuzhang Wu.   

Abstract

BACKGROUND: Renal tubular epithelial cells (TECs) function as antigen-presenting cells because they constitutively express MHC class II molecules and have the ability to present peptide antigen to CD4+T cells. However, the costimulatory signals provided by TECs for optimal T-cell activation have not been fully characterized. Increasing recognition of the importance of B7 dendritic cells (B7-DC) in immunoregulation raises the question of whether B7-DC is expressed on TECs and is involved in regulating TEC function.
METHODS: B7-DC on cultured human and murine TECs was detected by flow cytometry in vitro. Immunohistochemistry was performed on human kidney biopsies. Coculture experiments were performed to confirm the role of TEC-related B7-DC in regulating CD4+T-cell activation.
RESULTS: Data revealed that B7-DC is specifically expressed on TECs with inflammatory factor induced and diseased human kidney samples, including chronic glomerulonephritis, lupus nephritis, tubulointerstitial nephritis and renal cell carcinoma. B7-DC was a strong inhibitor of CD4+T-cell activation, as assessed by increased cytokine (interferon-gamma and interleukin-2) production and enhanced levels of T-cell activation marker CD69 in the presence of its blocking antibody. Blocking B7-DC/PD-1 enhanced antigen presentation. B7-DC is especially well expressed on TECs of diseased kidney samples and significantly down-regulates T-cell activation.
CONCLUSIONS: We speculate that B7-DC might play an important role in maintaining peripheral tolerance, and in protecting the epithelium from immune-mediated tubulointerstitial injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17048200

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  6 in total

Review 1.  Potential biofluid markers and treatment targets for renal cell carcinoma.

Authors:  Hiromi I Wettersten; Robert H Weiss
Journal:  Nat Rev Urol       Date:  2013-04-02       Impact factor: 14.432

2.  PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.

Authors:  Joseph M Obeid; Gulsun Erdag; Mark E Smolkin; Donna H Deacon; James W Patterson; Leiping Chen; Timothy N Bullock; Craig L Slingluff
Journal:  Oncoimmunology       Date:  2016-09-20       Impact factor: 8.110

Review 3.  A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.

Authors:  Caroline E Nunes-Xavier; Javier C Angulo; Rafael Pulido; José I López
Journal:  Curr Urol Rep       Date:  2019-01-15       Impact factor: 3.092

4.  The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides.

Authors:  Ewelina Grywalska; Iwona Smarz-Widelska; Ewelina Krasowska-Zajac; Izabela Korona-Glowniak; Karolina Zaluska-Patel; Michal Mielnik; Martyna Podgajna; Anna Malm; Jacek Rolinski; Wojciech Zaluska
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2017-08-02       Impact factor: 4.291

5.  The co-inhibitory molecule PD-L1 contributes to regulatory T cell-mediated protection in murine crescentic glomerulonephritis.

Authors:  Katrin Neumann; Annett Ostmann; Philippe Christophe Breda; Aaron Ochel; Frank Tacke; Hans-Joachim Paust; Ulf Panzer; Gisa Tiegs
Journal:  Sci Rep       Date:  2019-02-14       Impact factor: 4.379

6.  Soluble Programmed Cell Death Protein 1 and Its Ligand: Potential Biomarkers to Predict Acute Kidney Injury After Surgery in Critically Ill Patients.

Authors:  Jingyi Wang; Xi Zheng; Yijia Jiang; Huimiao Jia; Xiaocui Shi; Yue Han; Qingping Li; Wenxiong Li
Journal:  J Inflamm Res       Date:  2022-03-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.